Moneycontrol PRO
Upcoming Event:Attend Quants League - 5 Days Live Algorithmic Options Trading Virtual Conference @ just Rs. 600/- brought to you by Moneycontrol Pro. Register Now!
you are here: HomeNewsIndia

India has initiated an integrated response against COVID-19 pandemic: Harsh Vardhan

Speaking at the 8th BRICS STI Ministerial Meeting held on Friday, Vardhan said India is also hosting clinical trials for all the major vaccines, and about 20 vaccines are in different stages of development.

November 14, 2020 / 06:01 PM IST
File image

File image

From development of indigenous vaccines to novel point-of-care diagnostics, India has initiated an integrated response to overcome the unprecedented COVID-19 pandemic, Union minister Harsh Vardhan said on Saturday.

Speaking at the 8th BRICS STI Ministerial Meeting held on Friday, Vardhan said India is also hosting clinical trials for all the major vaccines, and about 20 vaccines are in different stages of development.

Two of them are in the most advanced stage of development. COVAXIN developed through ICMR-Bharat Biotech collaboration and COVISHIELD from the Serum Institute of India. Both are in Phase-III clinical trial stage, he added, "India has initiated an integrated response to overcome this unprecedented COVID-19 pandemic. ”

India has initiated an integrated response to overcome this unprecedented COVID-19 pandemic.

"From the development of indigenous vaccines, novel point-of-care diagnostics and therapeutic formulations based on traditional knowledge, to establishing research resources and offering services, Indian R&D entities, both public and private, are working relentlessly to develop effective interventions for combating the pandemic,” Vardhan, who holds the charge of Health Ministry as well as the Science and Technology Ministry, said.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Valery Falkov, Russian Minister of Science and Higher Education, Marcos Pontes, Brazilian Minister of Science, Technology and Innovation, Huang Wei, First Vice Minister of Science and Technology, China, Bonginkosi Emmanuel Nzimande, South African Minister of Higher Education, Science and Technology and several other dignitaries from member countries participated in the meeting.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

Vardhan said more than 100 start-ups have developed innovative products for COVID-19. He said the government has announced a $120 million grant for COVID-19 vaccine research. This is being provided for CovidSuraksha (Mission for protection from Covid) and is to be used purely for research and development in this field, he said.

"The grant does not cover the actual cost of the vaccine and its distribution expenses, which will be made separately as and when the vaccine is available,” he said.

Vardhan said India is also hosting clinical trials for all the major vaccine contenders.

Serum Institute of India, the world’s largest vaccine manufacturer, is conducting trials for the vaccine developed by Oxford University, he said.

"One of our pharma giants, Dr Reddy’s Laboratories, will distribute the Russian vaccine in India after conducting final-stage human trials and receiving regulatory approval,” the minister said.

Vardhan said India will actively contribute in implementation of BRICS STI Calendar of Activities 2020-21 and support continuation of scientific activities under BRICS MOU on Science, Technology and Innovation.

The BRICS member leaders applauded India for the 'SERBPOWER' (Promoting Opportunities For Women in Exploratory Research) scheme launched last month, the Department of Science and Technology said.

"We have recently launched a scheme 'SERBPOWER’ to encourage and support emerging as well as eminent women researchers to undertake R&D activities in areas of science and engineering. We may think of networking BRICS women scientists through a dedicated platform and mechanism,” he added.

Follow our full coverage of the coronavirus pandemic here.
PTI
first published: Nov 14, 2020 06:01 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark